Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,067 | 668 | 81.2% |
| Consulting Fee | $1,650 | 3 | 12.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $850.00 | 3 | 6.2% |
| Honoraria | $50.00 | 1 | 0.4% |
| Gift | $14.30 | 1 | 0.1% |
| Education | $6.26 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $4,099 | 176 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,613 | 41 | $0 (2022) |
| Gilead Sciences, Inc. | $1,253 | 71 | $0 (2023) |
| Janssen Biotech, Inc. | $1,103 | 69 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $987.53 | 68 | $0 (2023) |
| Merck Sharp & Dohme LLC | $590.37 | 40 | $0 (2022) |
| Ironwood Pharmaceuticals, Inc | $365.38 | 26 | $0 (2021) |
| Allergan, Inc. | $364.46 | 27 | $0 (2020) |
| Shire North American Group Inc | $354.53 | 10 | $0 (2019) |
| UCB, Inc. | $316.00 | 21 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $471.57 | 33 | AbbVie Inc. ($268.51) |
| 2022 | $1,072 | 56 | ABBVIE INC. ($550.90) |
| 2021 | $2,669 | 131 | AbbVie Inc. ($766.41) |
| 2020 | $1,664 | 95 | AbbVie Inc. ($452.80) |
| 2019 | $1,928 | 122 | AbbVie, Inc. ($384.67) |
| 2018 | $2,696 | 118 | Takeda Pharmaceuticals U.S.A., Inc. ($709.37) |
| 2017 | $3,137 | 122 | AbbVie, Inc. ($1,306) |
All Payment Transactions
677 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2023 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $11.56 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/13/2023 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/08/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: IMMUNOLOGY | ||||||
| 12/07/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.33 | General |
| Category: Neuroscience | ||||||
| 11/09/2023 | Sandoz Inc. | HYRIMOZ (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $7.88 | General |
| Category: IMMUNOLOGY | ||||||
| 09/28/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $10.58 | General |
| Category: IMMUNOLOGY | ||||||
| 09/21/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: IMMUNOLOGY | ||||||
| 09/14/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $9.38 | General |
| Category: IMMUNOLOGY | ||||||
| 09/06/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Gastroenterology | ||||||
| 09/06/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: Gastroenterology | ||||||
| 08/26/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: IMMUNOLOGY | ||||||
| 08/21/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $1.84 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: IMMUNOLOGY | ||||||
| 08/05/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $12.36 | General |
| Category: IMMUNOLOGY | ||||||
| 07/28/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: IMMUNOLOGY | ||||||
| 07/20/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $3.43 | General |
| Category: IMMUNOLOGY | ||||||
| 07/12/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.43 | General |
| Category: Neuroscience | ||||||
| 06/07/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/24/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.61 | General |
| 05/17/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.51 | General |
| 05/10/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $32.46 | General |
| Category: IMMUNOLOGY | ||||||
| 05/03/2023 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $2.01 | General |
| Category: VIROLOGY | ||||||
| 04/27/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: IMMUNOLOGY | ||||||
| 04/19/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 363 | 396 | $208,605 | $37,710 |
| 2022 | 11 | 535 | 583 | $306,440 | $59,340 |
| 2021 | 12 | 528 | 626 | $278,043 | $66,043 |
| 2020 | 11 | 561 | 698 | $270,180 | $60,579 |
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 48 | 48 | $62,400 | $10,009 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 95 | 119 | $22,610 | $7,373 | 32.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 93 | 93 | $25,575 | $6,195 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 37 | $10,175 | $3,488 | 34.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 38 | 38 | $36,670 | $3,337 | 9.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 15 | 15 | $12,975 | $2,835 | 21.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $7,000 | $2,563 | 36.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 26 | 26 | $31,200 | $1,911 | 6.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 138 | 178 | $33,080 | $11,608 | 35.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 120 | 120 | $32,330 | $9,954 | 30.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 44 | 44 | $72,600 | $9,627 | 13.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 64 | 64 | $22,735 | $8,034 | 35.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 53 | 53 | $59,205 | $5,299 | 8.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 34 | 42 | $11,275 | $3,710 | 32.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 30 | 30 | $37,275 | $3,426 | 9.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 16 | 16 | $11,960 | $3,175 | 26.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 11 | 11 | $10,390 | $2,185 | 21.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 13 | 13 | $13,790 | $2,053 | 14.9% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 12 | 12 | $1,800 | $270.52 | 15.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 129 | 172 | $30,485 | $11,843 | 38.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 74 | 88 | $22,575 | $9,341 | 41.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 59 | 59 | $21,795 | $8,420 | 38.6% |
| 46221 | Removal of external hemorrhoids by rubber banding | Office | 2021 | 14 | 32 | $17,898 | $7,951 | 44.4% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 35 | 35 | $49,300 | $7,551 | 15.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 53 | 53 | $55,675 | $5,590 | 10.0% |
About Dr. Mark Bierhoff, MD
Dr. Mark Bierhoff, MD is a Gastroenterology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568527372.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Bierhoff, MD has received a total of $13,637 in payments from pharmaceutical and medical device companies, with $471.57 received in 2023. These payments were reported across 677 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($11,067).
As a Medicare-enrolled provider, Bierhoff has provided services to 1,987 Medicare beneficiaries, totaling 2,303 services with total Medicare billing of $223,672. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Philadelphia, PA
- Active Since 12/22/2006
- Last Updated 03/21/2011
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1568527372
Products in Payments
- STELARA (Biological) $1,125
- Amitiza (Drug) $930.79
- XIFAXAN (Drug) $851.76
- Duopa (Drug) $800.00
- Humira (Biological) $609.21
- RINVOQ (Biological) $563.23
- Mavyret (Drug) $528.62
- HUMIRA (Biological) $485.01
- SKYRIZI (Biological) $462.38
- LINZESS (Drug) $460.08
- DIFICID (Drug) $393.82
- MAVYRET (Drug) $380.41
- Entyvio (Biological) $348.34
- Epclusa (Drug) $338.93
- Cimzia (Drug) $316.00
- Linzess (Drug) $266.19
- ZEPOSIA (Drug) $239.21
- ZENPEP (Drug) $222.31
- ENTYVIO (Biological) $189.21
- XELJANZ (Drug) $188.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Philadelphia
Xiaoli Ma, Md, MD
Gastroenterology — Payments: $717,441
Gary Lichtenstein, Md, MD
Gastroenterology — Payments: $416,696
Dr. Neilanjan Nandi, Md, MD
Gastroenterology — Payments: $334,815
Dr. David Lichtenstein, M.d, M.D
Gastroenterology — Payments: $263,694
James Lewis, Md, MD
Gastroenterology — Payments: $229,188
Mark Osterman, Md, MD
Gastroenterology — Payments: $142,430